All News

CancerNetwork® spoke with Jeffery Auletta, MD, about how the National Marrow Donor Program/Be The Match is using research initiatives to expand eligibility for stem cell transplants in for patient with acute leukemias and myelodysplastic syndrome.

Results of a phase 2 trial show that ibrutinib was capable of inducing responses in some patients with hairy cell leukemia who were previously treated with standard therapy options in a prior line.

Patients with unresectable hepatitis B virus–positive hepatocellular carcinoma have achieved significantly better overall survival and progression-free survival following treatment with sintilimab plus IBI305 vs sorafenib.

CancerNetwork® sat down with John Heymach, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk adjuvant immunotherapy for recurrence-free survival in resected non–small cell lung cancer.

Patients with hematologic malignancies and COVID-19 may experience a survival benefit after receiving convalescent plasma therapy.

Patients with relapsed/refractory mantle cell lymphoma experienced promising response rates after undergoing treatment with zanubrutinib.

Personalized risk assessments that utilize pathogenic variations can help detect CRC early in patients with Lynch Syndrome.

Phase 3 results demonstrating the superiority of the pembrolizumab plus lenvatinib combination vs standard chemotherapy served as a confirmatory trial for its approval in certain patients with advanced endometrial cancer.

Cynthia Ma, MD, PhD, explains key efficacy findings regarding HER-targeted therapy to treat patients with HER2-mutant breast cancer.

Sintilimab with gemcitabine plus platinum produced superior clinical benefit for patients with locally advanced or metastatic squamous cell non–small cell lung cancer when compared with gemcitabine plus platinum alone.

An oncology pharmacist talks secondary malignancies noted with tazemetostat in the treatment of follicular lymphoma.

Compared with a control therapy, ruxolitinib increased overall response and improved failure-free survival for patients with glucocorticoid-refractory or -dependent chronic graft-versus-host disease.

The combination of venetoclax and azacitidine will be considered as a treatment for patients with newly diagnosed, higher-risk myelodysplastic syndrome.

Treatment with trastuzumab, pertuzumab, and docetaxel appears to yield similar efficacy to trastuzumab emtansine in patients with ErbB2-positive breast cancer.

Robert A. Figlin, MD, spoke with CancerNetwork® about emerging second-line therapies as the paradigm of first-line treatment evolves for patients with metastatic clear cell renal cell carcinoma.

Early-phase data indicate that loncastuximab tesirine-lpyl elicited promising, long-lasting responses in patients with mantle cell lymphoma.

Data from a first-of-its-kind study indicated that unnecessary use of antibiotics may lead to early-onset colon cancer.

The combination of trilaciclib plus chemotherapy has been granted a fast track designation by the FDA for the treatment of locally advanced metastatic triple-negative breast cancer.

CancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.

Take a look at some of the important updates from CancerNetwork last week you might have missed in the world of oncology from the FDA and the journal ONCOLOGY.

This special edition of the “Oncology Peer Review On-The-Go” dives into recent updates and important treatment strategies for extensive-stage SCLC management.

Patients with metastatic triple-negative breast cancer being treated with leronlimab and carboplatin have experienced a decrease in cancer-associated macrophage-like cells and an increase in survival benefit.

Investigators will continue treating patients with GEN-1 plus neoadjuvant chemotherapy following the results of a pre-planned interim safety review of the phase 1/2 OVATION 2 study.

The phase 2 GIMEMA LAL1913 trial identified poor outcomes and increased minimal residual disease persistence among patients with Philadelphia-like acute lymphoblastic leukemia.

At ASCO 2021, Stephen Liu, MD, discussed his excitement for results of the IMpower010 trial of atezolizumab in patients with early-stage resected non–small cell lung cancer

Results from the phase 3 COSMIC-311 trial indicated that cabozantinib elicited a promising survival benefit in patients with radioiodine-refractory differentiated thyroid cancer.

Tazemetostat use only requires dosing modifications in a small percentage of patients, according to an oncology pharmacist.

Pembrolizumab plus chemotherapy as adjuvant/neoadjuvant therapy demonstrated positive even-free survival outcomes in the KEYNOTE-522 study for patients with triple-negative breast cancer.

Eric J. Sherman, MD, highlights several drugs that are being used to treat RET-positive thyroid cancer.

Eric J. Sherman, MD, examines the phase 3 COSMIC-311 trial with cabozantinib in radioiodine-refractory differentiated thyroid cancer.